Our results indicate that YTHDF2 plays an anti-inflammatory role by reducing the release of HMGB1 via inhibition of the IL-6R/JAK2/STAT1 pathway, demonstrating that targeting YTHDF2 may constitute a promising approach to sepsis treatment. Here, HMGB1 is linked to Sepsis.